uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~
Covered in this story
What has happened since
- American Tower is up 6.2% since this was published, 48 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AMT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on American Tower →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.